About Tymora Analytical

Tymora Analytical Operations provides diagnostic development, contract services and products for improved cancer research. Tymora’s primary goal is to enable the shift from tissue to liquid biopsy. Our new technologies allow detection of active  protein and phosphoprotein cancer markers directly from plasma, urine or saliva. As a platform to discover, validate and routinely detect diagnostic markers, our unique approach offers enormous potential to find signaling proteins in biofluids that were not previously accessible.

Tymora’s technologies have been recognized internationally as novel, highly-effective and cost-efficient approaches to carry out proteomic and phosphorylation analyses. Tymora has received multiple NSF and NIH SBIR/STTR grants to further develop new applications of the technologies.

Tymora is open to collaborations with partners interested in our technology for design and validation of early disease detection tests, cancer monitoring post-treatment, or for companion diagnostic assays for pipeline therapies.

Tymora Analytical Operations provides diagnostic development, contract services and products for improved cancer research. Tymora’s primary goal is to enable the shift from tissue to liquid biopsy. Our new technologies allow detection of active  protein and phosphoprotein cancer markers directly from plasma, urine or saliva. As a platform to discover, validate and routinely detect diagnostic markers, our unique approach offers enormous potential to find signaling proteins in biofluids that were not previously accessible.

Tymora’s technologies have been recognized internationally as novel, highly-effective and cost-efficient approaches to carry out proteomic and phosphorylation analyses. Tymora has received multiple NSF and NIH SBIR/STTR grants to further develop new applications of the technologies.

Tymora is open to collaborations with partners interested in our technology for design and validation of early disease detection tests, cancer monitoring post-treatment, or for companion diagnostic assays for pipeline therapies.

Tymora’s Leadership

Dr. W. Andy Tao

Chief Scientific Officer, Professor of Biochemistry at Purdue University


Dr. Anton B. Iliuk

President, Chief Technology Officer


Dr. Peter Kissinger

Business and Commercialization Mentor


Scientific and Business Advisory Board

Dr. Leroy Hood

Institute for Systems Biology, P4 Medicine Institute


Dr. Robert Geahlen

Purdue University


Dr. Fred Regnier

Purdue University, Perfinity Biosciences


Dr. Tim Peoples

Purdue Foundry